trifarotene
Sign in to saveAlso known as CD5789
Trifarotene, sold under the brand name Aklief, is a medication for the topical treatment of acne vulgaris. It is a retinoid; specifically, a fourth-generation selective retinoic acid receptor (RAR)-γ agonist.
Key facts
- Drug.image
- Trifarotene.svg
- Drug.image_class
- skin-invert-image
- Drug.tradename
- Aklief, Selgamis
- Drug.MedlinePlus
- a620004
- Drug.DailyMedID
- Trifarotene
- Drug.pregnancy_AU
- D
- Drug.pregnancy_category
- Contraindicated
- Drug.routes_of_administration
- Topical
- Drug.class
- Skin and mucous membrane agents
- Drug.ATC_prefix
- D10
- Drug.ATC_suffix
- AD06
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_UK
- POM
- Drug.legal_US
- Rx-only
- Drug.legal_status
- Rx-only
- Drug.CAS_number
- 895542-09-3
- Drug.PubChem
- 11518241
via Wikipedia infobox
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 459.241
Show 2 more facts
- chemical formula
- C₂₉H₃₃NO₄
- canonical SMILES
- CC(C)(C)C1=C(C=CC(=C1)C2=C(C=CC(=C2)C3=CC=C(C=C3)C(=O)O)OCCO)N4CCCC4
Sources (2)
via Wikidata · CC0
~2 min read
Encyclopedic overview
5 sectionsContents
- Medical uses
- Side effects
- Society and culture
- Legal status
- References
Trifarotene, sold under the brand name Aklief, is a medication for the topical treatment of acne vulgaris. It is a retinoid; specifically, a fourth-generation selective retinoic acid receptor (RAR)-γ agonist.
Trifarotene was granted orphan drug designation for the treatment of congenital ichthyosis by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). It was approved for medical use in the United States in October 2019. In December 2019, its labelling and package leaflet text received a decentralised approval for 16 European countries.
Excerpted from Wikipedia’s “trifarotene” article, available under the CC BY-SA 4.0 licence.